Program
ER2001
A development code. Also written as “ER2001 injection” and “ER2001 intravenous injection”.
Its studies are mostly in Huntington Disease, led by ExoRNA Bioscience.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| ExoRNA Bioscience | 31 open or running | phase 2since Jan 5, 2026 | May 25, 2023 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 25, 2023First study: early phase 1 study in Huntington DiseaseFirst studyNCT06024265 · 10 enrolled · China
- Jan 5, 2026Phase 2 study in Huntington DiseasePhase 2 reachedNCT07339514 · 27 enrolled · China
- Jan 7, 2026Early phase 1 study in Huntington DiseaseNCT07344519 · 8 enrolled · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07344519Huntington Disease · China | Early 1 | Completed | Jun 1, 2025 | 8 |
| NCT07339514Huntington Disease · China | 2 | Active, not recruiting | Apr 1, 2026 | 27 |
| NCT06024265Huntington Disease · China | Early 1 | Completed | Jan 31, 2025 | 10 |
How it is read
Names in the registry
- “ER2001 injection”, 2 entries
- “ER2001 intravenous injection”, 1 entry
Codes read as this program: ER2001.
Conditions, from the studies’ own filings
- Huntington Disease, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.